Sublingual L-Hyoscyamine (cas 101-31-5) for duodenal antimotility during ERCP: a prospective randomized double-blinded study
-
Add time:08/06/2019 Source:sciencedirect.com
BackgroundERCP is often made difficult by duodenal motility. Glucagon is typically used to inhibit this motility. L-Hyoscyamine (cas 101-31-5) is an antimuscarinic, anticholinergic agent shown to be a feasible intravenous alternative to glucagon.
We also recommend Trading Suppliers and Manufacturers of L-Hyoscyamine (cas 101-31-5). Pls Click Website Link as below: cas 101-31-5 suppliers
Prev:Prediction of hyoscyamine content in Datura stramonium L. hairy roots using different modeling approaches: Response Surface Methodology (RSM), Artificial Neural Network (ANN) and Kriging
Next:Development and validation of an LC/MS/MS method for the determination of l) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information
- Biochemical and structural characterization of recombinant hyoscyamine 6β-hydroxylase from Datura metel L.08/08/2019
- Development and validation of an LC/MS/MS method for the determination of l08/07/2019
- Prediction of hyoscyamine content in Datura stramonium L. hairy roots using different modeling approaches: Response Surface Methodology (RSM), Artificial Neural Network (ANN) and Kriging08/05/2019
- Comparative study between magnesium sulphate and L-Hyoscyamine (cas 101-31-5) on duodenal motility during ERCP under general anaesthesia: A prospective randomized study08/04/2019
- A modified QuEChERS method coupled with liquid chromatography-tandem mass spectrometry for the simultaneous detection and quantification of scopolamine, L-Hyoscyamine (cas 101-31-5), and sparteine residues in animal-derived food products08/03/2019